What one share of Aptevo Therapeutics holds
We are a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. We have developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs and have two clinical candidates and six preclinical candidates currently in development.
Aptevo Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$31.66 |
|---|---|
| Cash and investments | $6.90 |
| Book value | $4.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2025 | — | −$87.27 | — | — | — | $17.42 |
Common questions about Aptevo Therapeutics
How much does one share of Aptevo Therapeutics earn?
Over the last 12 months, Aptevo Therapeutics lost $31.66 for each share.
Does Aptevo Therapeutics pay a dividend?
Aptevo Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Aptevo Therapeutics’s book value per share?
Aptevo Therapeutics’s book value is $4.26 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Aptevo Therapeutics have?
Each share of Aptevo Therapeutics has $6.90 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.